Insider Buying: VolitionRx (NYSE:VNRX) CEO Buys $56,100.00 in Stock

VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds acquired 110,000 shares of the company’s stock in a transaction on Tuesday, October 14th. The shares were purchased at an average cost of $0.51 per share, with a total value of $56,100.00. Following the completion of the acquisition, the chief executive officer directly owned 2,534,847 shares in the company, valued at approximately $1,292,771.97. The trade was a 4.54% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Cameron John Reynolds also recently made the following trade(s):

• On Friday, September 12th, Cameron John Reynolds acquired 15,000 shares of VolitionRx stock. The shares were purchased at an average cost of $0.66 per share, with a total value of $9,900.00.
• On Tuesday, August 5th, Cameron John Reynolds acquired 78,125 shares of VolitionRx stock. The shares were purchased at an average cost of $0.64 per share, with a total value of $50,000.00.

VolitionRx Trading Down 0.7%

Shares of NYSE:VNRX opened at $0.44 on Friday. The stock has a market capitalization of $47.79 million, a P/E ratio of -1.23 and a beta of 1.27. VolitionRx Limited has a 1-year low of $0.40 and a 1-year high of $0.94. The business has a 50-day moving average price of $0.62 and a two-hundred day moving average price of $0.60.

Institutional Trading of VolitionRx

A number of large investors have recently bought and sold shares of VNRX. Armistice Capital LLC increased its stake in VolitionRx by 3.5% during the 2nd quarter. Armistice Capital LLC now owns 8,493,074 shares of the company’s stock worth $6,455,000 after purchasing an additional 286,644 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in VolitionRx during the 2nd quarter worth approximately $52,000. Silverberg Bernstein Capital Management LLC increased its stake in VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock worth $153,000 after purchasing an additional 60,209 shares in the last quarter. Finally, Blair William & Co. IL bought a new stake in VolitionRx during the 2nd quarter worth approximately $30,000. 8.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on VNRX. HC Wainwright reiterated a “buy” rating and issued a $2.50 price target on shares of VolitionRx in a research report on Tuesday, September 30th. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research report on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, VolitionRx presently has a consensus rating of “Buy” and a consensus target price of $3.50.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.